Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …

Chimeric antigen receptors (CARs) are engineered proteins designed to target T cells to
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …

Diffuse intrinsic pontine glioma (DIPG) remains a fatal brainstem tumor demanding
innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) …

Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective
responses in adults with glioblastoma, but the feasibility and tolerability of this approach is …

Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …

Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to
specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T–cell therapies …

New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are
resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and …

T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …

Targeting disialoganglioside (GD2) on neuroblastoma (NB) with T cells expressing a first-
generation chimeric antigen receptor (CAR) was safe, but the cells had poor expansion and …

The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs)
has shown remarkable curative potential against advanced B-cell malignancies, but multiple …